Administration of the same dose of a drug to all patients has the advantages of simplicity and ease of use.  However, data regarding the variability in platelet inhibition across patients highlights the potential importance of tailoring the antiplatelet or dose of an antiplatelet to the pharmacodynamic response of the patient.  Patients who do not achieve adequate inhibition in response to a dose of<unk>  are variably termed<unk>  non-responders” or<unk>  hyporesponders”.  A recent European Society of Cardiology working group has suggested the term "elevated platelet reactivity despite treatment".
This chapter reviews the underlying etiology and clinical relevance of<unk>  non-responsiveness.
Clopidogrel resistance
Aspirin desensitization
Activated protein C resistance
Clubbing pathophysiology
Warfarin over anticoagulation
Intraprocedural stent thrombosis
No-reflow phenomenon
High density lipoprotein pathophysiology